Literature DB >> 31975762

Sodium-Glucose Cotransporter 2 Inhibitor-Associated Prolonged Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes: A Case Report and Literature Review.

Ahmad Yehya1, Archana Sadhu1.   

Abstract

Entities:  

Year:  2020        PMID： 31975762      PMCID： PMC6969664          DOI： 10.2337/cd19-0035

Source DB:  PubMed          Journal:  Clin Diabetes        ISSN： 0891-8929


× No keyword cloud information.
  28 in total

Review 1.  Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.

Authors:  Darin Ruanpeng; Patompong Ungprasert; Jutarat Sangtian; Tasma Harindhanavudhi
Journal:  Diabetes Metab Res Rev       Date:  2017-06-16       Impact factor: 4.876

2.  SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A South Australian Clinical Case Series and Australian Spontaneous Adverse Event Notifications.

Authors:  Emily J Meyer; Genevieve Gabb; David Jesudason
Journal:  Diabetes Care       Date:  2018-02-13       Impact factor: 19.112

3.  Dapagliflozin-Associated Diabetic Ketoacidosis.

Authors:  Raja Chandra Chakinala; Anna P Chang; Shantanu Solanki; Khwaja F Haq; Ronald Cho
Journal:  Am J Ther       Date:  2018 Nov/Dec       Impact factor: 2.688

4.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Thomas A Zelniker; Julia F Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna-Maria Langkilde; Marc S Sabatine
Journal:  N Engl J Med       Date:  2018-11-10       Impact factor: 91.245

5.  Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview.

Authors:  Juan F Mosley; Lillian Smith; Emily Everton; Chris Fellner
Journal:  P T       Date:  2015-07

Review 6.  Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus.

Authors:  Muhammad A Abdul-Ghani; Ralph A DeFronzo
Journal:  Endocr Pract       Date:  2008-09       Impact factor: 3.443

Review 7.  Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

Authors:  Sunil Nair; John P H Wilding
Journal:  J Clin Endocrinol Metab       Date:  2009-11-05       Impact factor: 5.958

Review 8.  SGLT2 inhibitors in the treatment of type 2 diabetes.

Authors:  Farhad M Hasan; Mazen Alsahli; John E Gerich
Journal:  Diabetes Res Clin Pract       Date:  2014-03-11       Impact factor: 5.602

Review 9.  Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.

Authors:  Michael A Nauck
Journal:  Drug Des Devel Ther       Date:  2014-09-11       Impact factor: 4.162

10.  Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors.

Authors:  Wataru Ogawa; Kazuhiko Sakaguchi
Journal:  J Diabetes Investig       Date:  2015-09-06       Impact factor: 4.232
View more
  3 in total

1.  SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort.

Authors:  Fateen Ata; Zohaib Yousaf; Adeel Ahmad Khan; Almurtada Razok; Jaweria Akram; Elrazi Awadelkarim Hamid Ali; Ahmed Abdalhadi; Diaeldin Abdelgalil Ibrahim; Dabia Hamad S H Al Mohanadi; Mohammed I Danjuma
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

2.  Relationship of concomitant anti-diabetic drug administration with sodium-glucose co-transporter 2 inhibitor-related ketosis.

Authors:  Cheng-Wei Lin; Shih-Yuan Hung; I-Wen Chen
Journal:  J Int Med Res       Date:  2022-03       Impact factor: 1.671

Review 3.  Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy.

Authors:  Biff F Palmer; Deborah J Clegg
Journal:  Clin J Am Soc Nephrol       Date:  2021-02-09       Impact factor: 10.614
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.